PL2970427T3 - Kompozycja składająca się z antygenu związanego z ligandem z nadrodziny TNF - Google Patents

Kompozycja składająca się z antygenu związanego z ligandem z nadrodziny TNF

Info

Publication number
PL2970427T3
PL2970427T3 PL14723934T PL14723934T PL2970427T3 PL 2970427 T3 PL2970427 T3 PL 2970427T3 PL 14723934 T PL14723934 T PL 14723934T PL 14723934 T PL14723934 T PL 14723934T PL 2970427 T3 PL2970427 T3 PL 2970427T3
Authority
PL
Poland
Prior art keywords
composition comprised
tnf superfamily
antigen linked
superfamily ligand
ligand
Prior art date
Application number
PL14723934T
Other languages
English (en)
Inventor
Geoffrey W. STONE
Richard S. Kornbluth
Original Assignee
Geoffrey W. STONE
Richard S. Kornbluth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geoffrey W. STONE, Richard S. Kornbluth filed Critical Geoffrey W. STONE
Publication of PL2970427T3 publication Critical patent/PL2970427T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL14723934T 2013-03-15 2014-03-16 Kompozycja składająca się z antygenu związanego z ligandem z nadrodziny TNF PL2970427T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361794520P 2013-03-15 2013-03-15
US201361903378P 2013-11-12 2013-11-12
EP14723934.7A EP2970427B1 (en) 2013-03-15 2014-03-16 Composition comprised of antigen linked to a tnf superfamily ligand
PCT/US2014/030099 WO2014145355A1 (en) 2013-03-15 2014-03-16 Composition comprised of antigen linked to a tnf superfamily ligand

Publications (1)

Publication Number Publication Date
PL2970427T3 true PL2970427T3 (pl) 2020-06-01

Family

ID=50721893

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14723934T PL2970427T3 (pl) 2013-03-15 2014-03-16 Kompozycja składająca się z antygenu związanego z ligandem z nadrodziny TNF

Country Status (8)

Country Link
US (2) US10072064B2 (pl)
EP (1) EP2970427B1 (pl)
AU (1) AU2014233114B2 (pl)
CA (1) CA2907384C (pl)
DK (1) DK2970427T3 (pl)
ES (1) ES2775278T3 (pl)
PL (1) PL2970427T3 (pl)
WO (1) WO2014145355A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2754239T3 (es) * 2014-03-12 2020-04-16 Curevac Ag Combinación de vacunación y agonistas de OX40
WO2016112983A1 (en) 2015-01-15 2016-07-21 Biontech Ag Cytokine fusion proteins
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
WO2016153995A1 (en) 2015-03-20 2016-09-29 The Trustees Of The University Of Pennsylvania Vaccines with cd40 ligand as an adjuvant
US20200024326A1 (en) * 2018-06-14 2020-01-23 Nantbio, Inc. Tnf-type receptor-ligand fusion proteins and methods
US20220175920A1 (en) * 2019-03-27 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Recombinant proteins with cd40 activating properties
US20210147799A1 (en) * 2019-11-08 2021-05-20 The Broad Institute, Inc. Engineered antigen presenting cells and uses thereof
EP3984548A1 (en) * 2020-10-16 2022-04-20 Institut Pasteur Generation of lentiviral vectors enabling routing antigens to mhc-ii pathway and inducing cd4+ and cd8+ t-cell responses immune response in a host
WO2023201201A1 (en) * 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof
WO2024003353A1 (en) * 2022-07-01 2024-01-04 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9409768D0 (en) 1994-05-16 1994-07-06 Medical Res Council Trimerising polypeptides
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
US6482411B1 (en) 1999-08-27 2002-11-19 Board Of Regents, The University Of Texas System Methods of reducing bone loss with CD40 ligand
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
US6923958B2 (en) 2002-03-02 2005-08-02 The Scripps Research Institute DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
ES2605380T3 (es) 2005-05-06 2017-03-14 Providence Health & Services - Oregon Proteina de fusión OX40-inmunoglobulina trimérica y métodos de uso
AU2006321889A1 (en) * 2005-12-08 2007-06-14 University Of Louisville Research Foundation, Inc. In vivo cell surface engineering
US20090081157A1 (en) * 2006-01-09 2009-03-26 Richard Syd Kornbluth Immunostimulatory Combinations for Vaccine Adjuvants
EP2542679A1 (en) 2010-03-05 2013-01-09 Academisch Medisch Centrum bij de Universiteit van Amsterdam B-cell stimulating fusion proteins of an antigen with baff or april

Also Published As

Publication number Publication date
AU2014233114B2 (en) 2018-03-08
CA2907384A1 (en) 2014-09-18
AU2014233114A1 (en) 2015-10-15
WO2014145355A1 (en) 2014-09-18
US10072064B2 (en) 2018-09-11
US20160122412A1 (en) 2016-05-05
EP2970427B1 (en) 2019-12-25
CA2907384C (en) 2023-08-15
US20190010240A1 (en) 2019-01-10
ES2775278T3 (es) 2020-07-24
EP2970427A1 (en) 2016-01-20
DK2970427T3 (da) 2020-03-09
US10774149B2 (en) 2020-09-15

Similar Documents

Publication Publication Date Title
HK1253936A1 (zh) 結合ox40的抗體及其用途
PL2970427T3 (pl) Kompozycja składająca się z antygenu związanego z ligandem z nadrodziny TNF
HRP20180928T1 (hr) Protutijela za ligande bradikinin b1 receptora
HK1217500A1 (zh) 特異性結合 的抗體
GB2519397B (en) Apparatus to facilitate installation of a slide mechanism
GB201315851D0 (en) Antibodies to complex targets
ZA201507771B (en) Compounds and methods to isolate gold
IL245265B (en) Antibodies specific for fcrn
EP2861068A4 (en) METHODS ASSOCIATED WITH BEVACIZUMAB
IL244453A0 (en) Methods for determining response to medical treatment
SG11201600866TA (en) Joining to aluminium
HK1206610A1 (en) Fully human antibodies that bind to vegfr2 vegfr2
HK1218124A1 (zh) 使用抗 抗體的方法
DK2805823T4 (en) Plastrør i mindst to lag
GB201300324D0 (en) Improvements to letter-plates
GB201315308D0 (en) Improvements relating to audio visual interface
TH1401005842A (th) แอนติบอดีต่อ siglec-15 ที่ดัดแปลง cdr
GB201318272D0 (en) Improvements to cycles
GB201320829D0 (en) Preparation of functionalised materials
GB201320143D0 (en) Preparation of functionalised materials